GlobeNewswire·Sep 3, 2026, 5:15 PM ET

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Achieve Life Sciences' board approved stock option grants for 315,000 shares & restricted stock unit awards for 283,000 shares for 7 new employees under the 2024 Equity Inducement Plan.
Stock options carry an exercise price equal to the closing stock price on the grant date, with a four-year term & vesting of 25% after the first year & the remaining 75% in 36 monthly installments.
Restricted stock units vest over four years with 25% of shares vesting on each employment anniversary, contingent on continued service.
The grants were made as inducement material to employment in compliance with Nasdaq Listing Rule 5635(c)(4).
Cytisinicline is a plant-based alkaloid designed to treat nicotine dependence by interacting with brain receptors to reduce cravings & satisfaction from nicotine products.
Achieve's New Drug Application for smoking cessation is supported by two completed Phase 3 studies & an open-label safety study.
The company completed a Phase 2 study for e-cigarette cessation, held an end-of-Phase 2 meeting with the FDA, & received Breakthrough Therapy designation for the vaping cessation indication.